Y-mabs announces update on sada technology

New york, may 13, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that nai-kong v. cheung, md, phd, enid a. haupt endowed chair, pediatric oncology, memorial sloan kettering cancer center (“msk”) will present a research update on the company's sada technology platform at pegs boston virtual conference on may 13, 2021 at 1:20 p.m. eastern time. the sada technology was licensed by the company from msk and the massachusetts institute of technology (“mit”).
YMAB Ratings Summary
YMAB Quant Ranking